TransMedics Group Inc vs Teucrium Wheat Fund — how do they compare? TransMedics Group Inc trades at $87.08 (market cap $3.10B), while Teucrium Wheat Fund trades at $24.39. The key difference: Teucrium Wheat Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | WEAT | |
|---|---|---|
Market Cap | $3.10B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $150.42 | $26.00 |
52-Week Low | $61.99 | $19.88 |
Enterprise Value | $3.49B | — |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
WEAT (Teucrium Wheat Fund) trades at $24.36, up 1.46% over the past day, with a bullish technical signal driven by moving averages. Recent performance includes a 9.9% gain over the past month and a 25% year-to-date increase as of Zacks Investment Research on July 21, 2026. The USDA reduced its 2026 U.S. wheat production outlook to 1.56 billion bushels on May 12, 2026, influencing commodity-driven volatility.
The outlook remains positive due to strong momentum and inflation hedging appeal, but risks include agricultural supply shocks and macroeconomic pressures. Investors should weigh the fund's exposure to wheat price swings against potential for continued commodity strength amid ongoing inflation concerns highlighted by ETF Trends as of June 2026.
Trailing returns across standard periods
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →